×
About 2,765 results

ALLMedicine™ Chronic Myelogenous Leukemia Center

Research & Reviews  870 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expres...
https://doi.org/10.1080/16078454.2022.2066245
Hematology (Amsterdam, Netherlands); Zhang Y, Zeng X et. al.

May 12th, 2022 - T cell dysfunction is a common characteristic of patients with myeloid leukemia and is closely related to clinical efficacy and prognosis. In order to clarify the mechanisms leading to the T cell dysfunction, we characterized the gene expression p...

Unilateral Subhyaloid Hemorrhage as a Presenting Sign of Chronic Myeloid Leukemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063587
The American Journal of Case Reports; Almater AI, Alhadlaq GS et. al.

Apr 30th, 2022 - BACKGROUND Chronic myelogenous leukemia (CML) is a malignant myeloproliferative neoplasm of pluripotent stem cell origin. Ophthalmic manifestation as an initial presentation in cases of CML is extremely rare. Frequently, ocular lesions in CML are ...

Anti-N-methyl-D-aspartate receptor encephalitis associated with chronic myelogenous leu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034597
BMC Neurology; Yu Y, Liu JL et. al.

Apr 25th, 2022 - Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most frequent autoimmune paraneoplastic encephalitis, and is primarily associated with ovarian teratomas. Here, we report the first case of a patient diagnosed with chronic myelogenous...

see more →

Guidelines  5 results

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myel...
https://doi.org/10.1007/s12185-017-2330-1
International Journal of Hematology; Usui N

Sep 25th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Chronic Myelogenous Leukemia, Version 1.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Radich JP et. al.

Nov 15th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2012.0009
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Abboud CN et. al.

Jan 10th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2009.0065
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Berman E et. al.

Nov 3rd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatmen...
https://doi.org/10.1093/annonc/mdn091
Annals of Oncology : Official Journal of the European Soc... Hochhaus A, Dreyling M et. al.

May 9th, 2008 - Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.|2008|Hochhaus A,Dreyling M, ,|diagnosis,epidemiology,therapy,

see more →

Drugs  23 results see all →

Clinicaltrials.gov  91 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT01518556

Apr 15th, 2022 - Up to nowadays, a standard induction therapy for acute myeloid leukemia(AML) has consisted of cytarabine 100-200 mg per square meter of body surface area(BSA) per day continuous infusion for 7 days with idarubicin 12 mg per square meter or daunoru...

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT00658814

Mar 28th, 2022 - PRIMARY OBJECTIVES: I. To test whether outcomes of patients of age 60 or older with previously untreated non-M3 acute myeloid leukemia treated with azacitidine plus gemtuzumab ozogamicin are sufficient to warrant phase III investigation. II. To es...

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
https://clinicaltrials.gov/ct2/show/NCT04188405

Mar 11th, 2022 - PRIMARY OBJECTIVE: I. To determine the efficacy of the regimen, as defined by the rate of complete remission (CR) or CR with incomplete count recovery (CRi). SECONDARY OBJECTIVES: I. To determine efficacy outcomes, including rate of minimal residu...

see more →

News  113 results

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer
https://www.onclive.com/view/dr-ron-bose-on-her2-gene-mutations-in-breast-cancer

Oct 6th, 2021 - Ron Bose, MD, PhD, assistant professor in the Division of Oncology at Washington University School of Medicine and the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer. Overall, Bose ...

Life Expectancy Still Lower for Blood or Marrow Transplant Recipients
https://www.medpagetoday.com/hematologyoncology/hematology/94425

Sep 9th, 2021 - While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study...

Clinical Edge Journal Scan Commentary: CML September 2021
https://www.mdedge.com/hematology-oncology/article/245751/cml/clinical-edge-journal-scan-commentary-cml-september-2021
Javier Pinilla-Ibarz MD, PhD

Sep 7th, 2021 - Javier Pinilla-Ibarz MD, PhD Chronic myelogenous leukemia ( CML) is a relatively rare leukemia in pediatric population and although allogenic bone marrow transplant used to be commonly used even in the earlier times of TKIs therapy, the superior s.

No Age Limit for Bone Marrow Transplantation
https://www.onclive.com/view/no-age-limit-for-bone-marrow-transplantation

Aug 17th, 2021 - Rainer Storb, MD Member, Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for...

Dr. Zelenetz on Treating Hematologic Malignancies
https://www.onclive.com/view/dr-zelenetz-on-treating-hematologic-malignancies

Aug 17th, 2021 - Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancie...

see more →

Patient Education  4 results see all →